Skip to main content

Table 4 Clinical performance of the most efficient test to detect CIN1+, CIN2+ and CIN3+ lesions

From: Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1–2 lesions

  HPV infection Test Sensitivity (%) Specificity (%) PPV (%) NPV (%)
CINI+ no p16/Ki-67 88.64 (75.4–96.2) 51.43 (34–68.6) 69.9 (64.6–75) 78.2 (68.5–85.7)
  HPV-16 and/or 58 p16/Ki-67/HPV load 90.8 (85.3–94.3) 86.96 (66.4–97.2) 98 (95.1–99.3) 57.1 (47.8–62.5)
  others p16/Ki-67 81.36 (69.1–90.3) 84.63 (65.1–95.6) 92.3 (85.5–97.6) 66.67 (58.1–73.9)
CINII+ no p16/Ki-67 94.12 (71.3–99.9) 88.71 (78.1–95.3) 69.6 (54.8–80) 98.2 (92.2–100)
  HPV-16 and/or 58 p16/Ki-67/HPV load 88.89 (82.3–93.6) 92.16 (81.1–97.8) 95.8 (92.6–99.1) 75.8 (67.6–82)
  others p16 94.59 (81.8–99.3) 75 (60.4–86.4) 74.5 (65.9–82.3) 94.7 (86–99)
CINIII+ no p16/Ki-67 100 (47.8–100) 90.54 (81.5–96.1) 41.7 (26.7–44.4) 100 (96.5–100)
  HPV-16 and/or 58 p16/Ki-67/HPV load 86.6 (78.2–92.7) 77.53 (67.4–85.7) 80.8 (75.6–85.4) 84.1 (78.4–89.6)
  others p16/Ki-67 84.21 (60.4–96.6) 96.97 (89.5–99.6) 88.9 (72.4–97.5) 95.5 (89.8–99)